Dr Charles Harrington
Chief Scientific Officer and Head of Non-Clinical Development
Dr Harrington has extensive research experience in the field of neurodegenerative diseases and is author of more than 50 publications and co-inventor in 12 patent applications in this area.
He has collaborated with Professor Wischik for over 20 years, developing assays for screening agents having the potential to prevent the tau pathology that is the hallmark of Alzheimer’s disease.
“Through an understanding of the basis of the science behind diseases, we can resolve complexity and provide a treatment for debilitating neurodegenerative disorders.”
Dr Charles Harrington
Chief Scientific Officer and Head of Non-Clinical Development
